The deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate.
Atrium Therapeutics became independent on February 26, 2026, when Avidity Biosciences distributed all of its shares at one Atrium share for every ten Avidity shares. Atrium began trading on Nasdaq as RNA on February 27, and it signed an amended license and a transition services agreement with Avidity the same day.
Avidity holders of record on February 12, 2026 would receive Atrium shares, but the distribution depends on Avidity's merger with Novartis and is taxable to holders. Avidity may instead sell Atrium to a third party, in which case no distribution would occur.
Questions about Atrium Therapeutics
Has Atrium Therapeutics raised money recently?
Our latest story on this, dated Oct 8, 2026: "Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share". The story links the filing or release it is based on. Read the story.
Is Atrium Therapeutics involved in a merger or acquisition?
Our latest story on this, dated Feb 26, 2026: "Atrium Therapeutics spin-off from Avidity to give holders one share per ten". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Atrium Therapeutics?
Atrium Therapeutics, Inc. trades under the ticker RNA on NASDAQ.
Where is Atrium Therapeutics listed?
Atrium Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Atrium Therapeutics?
The SEC Central Index Key (CIK) for Atrium Therapeutics, Inc. is 2093101. Its filings are on SEC EDGAR.
How many shares does Atrium Therapeutics have outstanding?
17,105,643 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Atrium Therapeutics listed under?
Our directory records Atrium Therapeutics, Inc. under United States.
What does Atrium Therapeutics do?
Our directory classifies Atrium Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Atrium Therapeutics?
The ISIN recorded for Atrium Therapeutics, Inc. is US04965N1046.
Does aibio.space cover Atrium Therapeutics?
aibio.space lists Atrium Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Atrium Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Atrium Therapeutics (RNA) stock news?
Our latest story on Atrium Therapeutics, dated Oct 8, 2026: "Atrium Therapeutics agrees to private placement of about $50 million at $7.93 a share". The deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate. Source.
How long will Atrium Therapeutics's cash last?
From our story of Oct 8, 2026: The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate. Source.
How much cash does Atrium Therapeutics have?
From our story of Feb 26, 2026: The unaudited pro forma balance sheet shows cash of $270,000 thousand after the transfer, against no historical cash. Source.
Is Atrium Therapeutics a smaller reporting company?
SEC records list Atrium Therapeutics, Inc.'s filer category as: <br>Emerging growth company.
Investor discussion: Atrium Therapeutics
Members talk about Atrium Therapeutics (RNA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Atrium Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:RNA on TradingView.
SEC filings and registration
SEC name
Atrium Therapeutics, Inc.
CIK
2093101
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
RNA (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
3020 CALLAN ROAD, SAN DIEGO, CA, 92121
Phone
858-401-7900
Shares outstanding
17,105,643 as of 2026-08-03 (10-Q filed 2026-08-13)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Atrium Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RNA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio